Peptide therapy: types, benefits, risks & what to know in 2026

By Kokei Abam, RDN · Registered Dietitian Nutritionist

Published September 30, 2026 · Last reviewed September 30, 2026 · 18 min read

Peptides are short sequences of amino acids that can act as powerful biological signals, binding to specific receptors and changing how cells and tissues function. Peptide therapy harnesses this biology to mimic or replace signals naturally produced by the body, or to modify pathways involved in disease. Insulin, for example, has transformed the treatment of diabetes for more than a century. At the same time, other peptides are being investigated for therapeutic effects that remain far less certain.

Peptide therapy is therefore an umbrella term, used for established medicines as well as treatments still being studied or offered outside approved indications. The evidence, regulatory status, and clinical experience behind these uses can differ substantially. If you are considering or already using a peptide, understanding where that particular therapy stands in medicine is essential.

What are peptides, and what is peptide therapy?

Peptides are chains of amino acids linked by peptide bonds. The sequence of amino acids determines their structure and biological activity. Many peptides act as signaling molecules by binding to specific receptors and influencing cellular processes such as appetite or immune function. Even though some peptides, including insulin, function as hormones themselves, others serve different signaling and biological roles, including tissue repair and metabolism.

Peptides and proteins are both chains of amino acids, with the distinction generally based on chain length and structural complexity. There is no universally accepted amino-acid length that marks the boundary between them. According to Wang et al. (2025),¹ the International Union of Pure and Applied Chemistry uses terms such as oligopeptide and polypeptide for chains of different lengths, while proteins generally consist of longer, folded polypeptide chains.

Peptides and steroids can both influence physiological processes related to hormones, body composition, and physical performance, but they are chemically distinct. Peptides are amino-acid chains, whereas steroids are fat-soluble compounds derived from cholesterol that can pass through cell membranes and influence hormone activity inside cells.

Peptide therapy is the therapeutic use of a peptide to produce a specific biological effect. The term encompasses established peptide medicines, off-label and investigational uses, compounded products, and peptides promoted in wellness and performance settings.

How do peptide therapies work?

Peptide therapies work by interacting with specific molecular targets in the body, most commonly receptors. A receptor is a protein that binds specific molecules based on their molecular structure. When a peptide binds to its receptor, it can change the receptor's activity and trigger signaling inside the cell. The resulting effect depends on the receptor involved and how the peptide interacts with it.

When a therapeutic peptide acts through a receptor on the cell surface, the peptide does not need to enter the cell. Instead, binding to the receptor changes its activity and activates or inhibits signaling inside the cell. These signals can alter cellular functions such as hormone secretion or metabolic activity. Fetse et al. (2023) describe therapeutic peptides that act as agonists or antagonists at cell-surface receptors, producing different effects depending on how they interact with their targets.²

An agonist binds to a receptor and activates it, producing a response through that signaling pathway. An antagonist binds without activating the receptor and can prevent another molecule from doing so. The effect of receptor binding therefore depends not only on which receptor a peptide targets, but also on what the peptide does when it binds.

This helps explain why peptide therapies can produce very different physiological effects. A peptide acting on a receptor involved in appetite regulation may alter hunger and satiety signaling, while one acting on a receptor involved in hormone secretion may change the release of a particular hormone. Even peptides acting on related receptors can behave differently because differences in their molecular structure affect how they bind and how the receptor responds.

Cell-surface receptors are not the only possible targets. Most peptides have limited ability to cross cell membranes, but some can enter cells through processes such as endocytosis or other mechanisms that allow cellular entry. Once inside, they can interact with intracellular targets and influence cellular activity through mechanisms different from those of cell-surface receptor signaling.

Where are peptides used or studied?

Metabolic disease and weight management

Peptide-based therapies have established roles in metabolic disease, particularly type 2 diabetes and obesity. Insulin replaces or supplements insulin needed to regulate blood glucose, while semaglutide and other GLP-1 receptor agonists improve glucose control, with some also FDA-approved for chronic weight management. Chui et al. (2026) describe newer approaches involving fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15), which are being studied for obesity and related metabolic conditions.³

Semaglutide and tirzepatide are FDA-approved for chronic weight management in eligible adults, while both are also approved to improve blood glucose control in adults with type 2 diabetes. The widespread use of these medicines contributed to shortages of both injections, which FDA determined were resolved in December 2024 for tirzepatide and February 2025 for semaglutide. For more on this class specifically, see our GLP-1 medications explainer.

Renke et al. (2026) reviewed peptide therapies for metabolic and endocrine conditions, covering established treatments for obesity and type 2 diabetes alongside newer, unapproved peptides being explored for uses such as performance enhancement, tissue regeneration, skin rejuvenation, and longevity.⁴ The review noted that most of these newer peptides lack sufficient evidence to establish their safety and clinical use in humans.

Endocrine and hormonal disorders

Growth hormone-releasing hormone (GHRH) and its synthetic analogs are being investigated for their ability to modify growth hormone signaling. GHRH is a peptide hormone produced in the hypothalamus that stimulates the pituitary gland to release growth hormone. Researchers have developed GHRH agonists that enhance this signaling and antagonists that inhibit it, allowing the pathway to be studied and potentially modulated in different ways. Schally et al. (2025) reviewed the development of these GHRH analogs and their potential therapeutic applications, including approaches intended to alter growth hormone activity in conditions in which this signaling pathway may be clinically relevant.⁵

The research therefore extends beyond simply replacing a deficient hormone. GHRH agonists and antagonists provide ways of increasing or suppressing growth hormone signaling at an earlier point in the hormonal pathway. However, the therapeutic applications discussed by Schally et al. remain under investigation, and the evidence is not sufficient to present these approaches as established treatments for endocrine disorders.

Skin, wound healing, and tissue repair

GHK-Cu is being studied for skin regeneration and repair. In chronic wound research, bioactive and synthetic peptides are being investigated for antimicrobial, anti-inflammatory, angiogenic, and tissue-regenerative effects. Kamil et al. (2025) reviewed these applications, including peptide-based hydrogels designed to keep therapeutic peptides at the wound site and release them gradually to support tissue repair.⁶

For aesthetic applications, Mokhtar et al. (2026) reviewed research on GHK-Cu and its effects on collagen and glycosaminoglycan production, angiogenesis, cellular proliferation, and inflammatory signaling.⁷ Their review included 20 studies, 18 of which were preclinical and two of which were randomized controlled trials. The clinical studies reported greater patient satisfaction after laser resurfacing and reductions in wrinkle volume and depth compared with controls. Microneedles and liposomes were also investigated as ways to improve GHK-Cu delivery through the skin.

Sexual health

Bremelanotide is a melanocortin receptor agonist that was engineered after research into pigment-producing melanocortin peptides unexpectedly revealed potent effects on sexual function. It is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. In the phase 3 RECONNECT trials, Goldstein et al. (2025) reported significantly greater improvements in sexual arousal and orgasm measures with bremelanotide than with placebo, with differences evident at four weeks and maintained through 24 weeks.⁸ These findings provide evidence of effects on sexual arousal and orgasm in addition to its primary indication for low sexual desire.

Pujia et al. (2022) reviewed C-peptide replacement for sexual and reproductive complications associated with type 1 diabetes, where C-peptide deficiency has been proposed as one contributor.⁹ The review describes experimental and human findings involving erectile function, sperm count and motility, testosterone levels, and nerve function. C-peptide replacement remains investigational, and further research is needed to determine its clinical usefulness.

Growth hormone, body composition, and physical recovery

Growth hormone secretagogues, including growth hormone-releasing peptides (GHRPs) such as GHRP-5, as well as ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 (a growth hormone fragment), are being investigated for their effects on growth hormone signaling, body composition, and physical recovery. These peptides act at different points in the growth hormone pathway, with some stimulating growth hormone release and others studied for effects mediated through growth hormone signaling. Within this group, tesamorelin is currently FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, while sermorelin was previously FDA-approved for growth hormone deficiency-related short stature in children.

Králík et al. (2026) examined eight GHRPs, characterizing their structures, thermal stability, and interactions with model membranes to better understand the biochemical properties of peptides that influence growth hormone secretion.¹⁰ A separate review by Rahman et al. (2026) examined ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 in relation to IGF-1 signaling, tissue regeneration, neuromuscular recovery, body composition, and physical recovery.¹¹ The review describes research into these peptides for outcomes such as muscle repair and changes in body composition, while noting that clinical trials evaluating these applications are limited.

Neurological, cognition, and sleep research

In Alzheimer's disease and Parkinson's disease, Chan et al. (2024) reviewed peptides including vasoactive intestinal peptide (VIP), glucagon-like peptide (GLP), glutathione, cholecystokinin, neurotensin, and small humanin-like peptides (SHLPs), examining their potential effects on neuroinflammation, cellular stress, neuronal survival, and brain energy metabolism.¹² The review describes these peptides primarily in preclinical research into mechanisms involved in neurodegeneration.

De Giorgi et al. (2025) reviewed GLP-1 receptor agonists, including semaglutide and liraglutide, for their potential use in Alzheimer's disease, Parkinson's disease, and other major neurocognitive disorders.¹³ Their analysis examined mechanistic, preclinical, and human evidence, including studies of neuroinflammation, brain metabolism, cognition, and dementia risk.

For sleep and cognition, Thomas et al. (2024) studied collagen peptide supplementation in physically active men with sleep complaints, finding fewer nighttime awakenings and improved performance on one cognitive measure, although most other sleep and cognitive outcomes were unchanged.¹⁴ Bell et al. (2024) examined carnosine, anserine, and other histidine-containing dipeptides, as well as beta-alanine, in a meta-analysis of randomized trials and found improved delayed recall, with no significant effects on several other cognitive measures.¹⁵

Orthopedics, musculoskeletal health, and recovery

When Rahman et al. (2026) reviewed BPC-157, TB-500, and GHK-Cu for their potential in tissue repair, tendon healing, soft-tissue regeneration, and recovery, they described mechanisms involving angiogenesis, extracellular matrix remodeling, and fibroblast activity, including applications in chronic soft-tissue healing, postoperative recovery, and tendon-to-bone integration.¹¹

They also reviewed ipamorelin, CJC-1295, tesamorelin, and sermorelin as growth hormone secretagogues, along with AOD-9604, a growth hormone fragment, investigated in relation to IGF-1 signaling, satellite-cell repair, muscle recovery, and cartilage repair. Epithalon, delta sleep-inducing peptide (DSIP), and pinealon were discussed as recovery-enhancing peptides studied for effects on circadian and mitochondrial pathways. The review notes a lack of clinical trials evaluating these orthopedic applications.

FDA-approved, compounded, and investigational peptides: what is the difference?

FDA-approved peptide medications

Peptide medicines are not new to clinical medicine. Insulin has been used for more than a century to replace the hormone needed to regulate blood glucose. Glucagon is used to rapidly raise blood glucose during severe hypoglycemia, and desmopressin, a synthetic analog of the peptide hormone vasopressin, has established uses in conditions including central diabetes insipidus. More recently, semaglutide and tirzepatide have brought peptide-based medicines into widespread use for type 2 diabetes and chronic weight management. When the FDA approves a peptide medication, it has reviewed evidence supporting its safety and effectiveness for a specific indication and population. Approval establishes the conditions under which the medication can be used, including its indication, dosing, contraindications, warnings, and other information contained in the approved prescribing information.

Approval does not mean that the medication is risk-free or that every potential use of the peptide has been established. A clinician may prescribe an FDA-approved medication for an off-label use, but that particular use has not undergone the FDA's determination of safety and effectiveness for that indication.

503A compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional, patient-specific compounding. A compounded drug must generally be prepared for an identified individual patient pursuant to a valid prescription and by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician.

State boards of pharmacy provide day-to-day oversight of pharmacy practice within their jurisdictions, while FDA retains federal oversight and enforcement authority over compounded drugs.

The prescription alone, however, does not make every substance eligible for compounding. FDA's requirements for "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" specify which bulk substances may be used and under what conditions.¹⁶ Depending on the substance, it may need to meet an applicable USP or National Formulary standard, be a component of an FDA-approved drug, or appear on FDA's 503A Bulks List. In other words, 503A provides a pathway for individualized compounding, but both the compounder and the substance must meet the federal requirements.

503B outsourcing facilities

Section 503B provides a federal framework for facilities registered as human drug compounding outsourcing facilities. These facilities can compound and distribute certain drugs without obtaining a patient-specific prescription for each order, subject to the requirements of the 503B framework.

Registration brings the facility under FDA oversight and subjects it to current good manufacturing practice (CGMP) requirements. Registered outsourcing facilities are inspected by FDA according to a risk-based approach and must report adverse events and other required product information to the agency.

Importantly, 503B registration is not FDA approval of the compounded products. These drugs do not undergo the FDA's premarket review for safety and effectiveness required for approved medications. Registration also does not certify that a facility is currently compliant with CGMP or other 503B requirements. FDA inspection findings reflect the conditions observed at the time of inspection, and a facility's compliance status can change afterward.

Category 1, 2, 3, and the 503A Bulks List

FDA uses three interim categories while evaluating bulk drug substances that have been nominated for possible inclusion on the 503A Bulks List, the FDA list of bulk drug substances that may be used in compounding under the conditions of Section 503A.

• Category 1 contains substances with sufficient supporting information for FDA to evaluate the nomination and for which the agency's interim enforcement policy may apply when its stated conditions are met.
• Category 2 contains substances that also have sufficient information for evaluation but for which FDA has identified significant safety concerns; the Category 1 interim policy therefore does not apply.
• Category 3 contains substances for which the nomination does not provide enough supporting information for FDA to evaluate the substance, so these substances are also outside the Category 1 interim policy.

The regulatory history of these peptide nominations in 2026 illustrates how their status can change as FDA evaluates them. On April 22, 2026, FDA removed several peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon, and emideltide (DSIP), from Category 2 after their nominations were withdrawn. On May 14, 2026, non-injectable GHK-Cu was added to Category 1 after the nominator clarified that its withdrawal applied only to the injectable form.

On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC), an advisory committee that provides FDA with expert recommendations on pharmacy compounding issues, considered seven peptide substances for possible inclusion on the 503A Bulks List. The committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, but did not recommend emideltide. These recommendations are advisory; they do not themselves change a substance's regulatory status or place it on the 503A Bulks List.

Placement on the 503A Bulks List is a separate FDA action completed through rulemaking. A substance leaving an interim category or receiving a favorable PCAC recommendation does not, by itself, mean that the substance has been added to the final list or that its use in compounding has been authorized.

Investigational and research-only products

A peptide can be scientifically investigated without being FDA-approved or routinely available as a prescription medication. Investigational refers to a product being studied to determine whether it may be safe and effective for a particular use. Clinical trials conducted under FDA oversight are part of this process, and the evidence generated through these studies may ultimately support a future application for FDA approval. Until that process is complete, however, research findings do not establish the peptide as an approved treatment.

This is distinct from products marketed online as "research use only" or similar designations. Such products may be sold with language stating that they are not intended for human use, even when their marketing or presentation makes them attractive to people seeking to self-administer them. The fact that a product is available for purchase does not establish that it is FDA-approved, appropriate for human use, or lawfully marketed for self-administration. Conversely, the absence of FDA approval alone does not establish that an investigational peptide is ineffective; it means that FDA has not approved it for the proposed use.

Who oversees compounded medications?

Compounded medications are subject to federal and state requirements, with additional standards and oversight from several professional and regulatory bodies. Each has a specific role in how compounded medications are prepared, regulated, and evaluated.

Body / standard	What it does
U.S. Food and Drug Administration (FDA)	Enforces federal requirements for drug compounding, including the framework for 503B outsourcing facilities. Registers and inspects outsourcing facilities, takes enforcement action, conducts recalls, and determines which bulk drug substances may be used under applicable federal provisions.
State boards of pharmacy	License and regulate pharmacies within their jurisdictions and generally have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered as 503B outsourcing facilities. Requirements vary by state.
National Association of Boards of Pharmacy (NABP)	An association of state boards of pharmacy that supports its member boards through programs and services involving pharmacy licensure, verification, examinations, and public-health initiatives. Not a federal regulator.
United States Pharmacopeia (USP)	Develops compounding standards, including USP <795> for nonsterile preparations, USP <797> for sterile preparations, and USP <800> for hazardous drugs. Develops standards; does not regulate pharmacies or approve individual compounded drugs.
Current Good Manufacturing Practice (CGMP)	A federal manufacturing-quality framework governing how drugs are manufactured and controlled. 503B outsourcing facilities are subject to CGMP requirements. CGMP is a set of requirements, not an organization or accreditation.
Pharmacy Compounding Advisory Committee (PCAC)	An FDA advisory committee that reviews scientific, technical, and medical issues concerning compounding and makes recommendations to FDA. Recommendations are advisory; FDA retains regulatory decision-making authority.
Independent accreditation	Voluntary third-party accreditation can evaluate a pharmacy's compounding practices against defined standards. For example, PCAB accreditation (administered by ACHC) evaluates sterile and nonsterile compounding against standards aligned with USP requirements. Accreditation is separate from state licensure and FDA registration.

How strong is the evidence for peptide therapy?

The evidence for peptide therapy varies by the specific peptide and its intended use. The examples below show what has actually been demonstrated and where claims remain under study or extend beyond the available evidence.

Evidence category	Example	What has been demonstrated	What remains studied or extends beyond the evidence
FDA-approved treatment for a defined indication	Semaglutide	FDA-approved for type 2 diabetes and chronic weight management in specified populations.	Other proposed uses are not automatically established by those approvals.
FDA-approved treatment with a narrow indication	Bremelanotide	FDA-approved for acquired, generalized HSDD in premenopausal women. Phase 3 RECONNECT data also demonstrated improvements in sexual arousal and orgasm measures compared with placebo.	The approved indication does not extend to sexual performance enhancement, men, or postmenopausal women.
Human clinical evidence with important limitations	GHK-Cu	A 2026 systematic review identified 20 studies (18 preclinical, 2 randomized clinical trials) reporting greater patient satisfaction after laser resurfacing and reductions in wrinkle volume and depth.	The evidence base remains small and predominantly preclinical; broader skin regeneration and anti-aging claims remain under study.
Early human evidence	CJC-1295	A randomized, placebo-controlled study in healthy adults demonstrated sustained increases in growth hormone and IGF-1 after administration (Teichman et al., 2006).	These findings demonstrate a pharmacologic effect, not established benefits for muscle growth, fat loss, recovery, or athletic performance.
Primarily animal or in-vitro evidence	Investigational GHRH agonists/antagonists	Preclinical studies have reported effects involving wound healing, inflammation, neuroprotection, diabetes, obesity, cardiovascular disease, and other conditions.	Therapeutic effectiveness and safety for these applications remain to be established in humans.
Common wellness or performance claims that exceed available evidence	BPC-157, TB-500, ipamorelin, AOD-9604	Research has identified biological effects and, for some compounds, limited human findings.	Claims involving tissue repair, enhanced recovery, muscle growth, body composition, or performance extend beyond the strength of available clinical evidence.

What are the risks and side effects of peptide therapy?

The risks of peptide therapy vary considerably by the substance and how it is used.

Drug-specific adverse effects: Each peptide has its own adverse-effect profile based on its pharmacologic activity. Semaglutide, for example, commonly causes gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and constipation, while bremelanotide is associated with nausea, transient increases in blood pressure, and focal hyperpigmentation.

Route-related risks: The mode of administration can introduce additional risks. These risks may be particularly important when a peptide is administered by injection, especially through a route for which human safety data are limited. One example is ipamorelin. In a 2014 study by Beck et al., intravenous ipamorelin was investigated for postoperative ileus in adults undergoing abdominal surgery.¹⁷ Two patients who received ipamorelin experienced fatal postoperative complications, although the FDA noted in its October 2024 review that it was unclear whether the deaths were related to ipamorelin. The same study reported higher rates of hypokalemia and hyperglycemia in the ipamorelin group.

Allergy, immunogenicity, and product quality: For some compounded peptides, the safety concerns extend beyond the peptide's intended pharmacologic effects. In its evaluations of Category 2 bulk drug substances, the FDA identified potential immunogenicity associated with peptide aggregation and peptide-related impurities, as well as concerns about API characterization and limited human safety information for several peptides, including BPC-157, CJC-1295, GHRP-2, GHRP-6, ipamorelin, AOD-9604, GHK-Cu, and TB-500. These concerns also include sterility, contamination, and potency for compounded products. Poor-quality compounded drugs can contain contaminants or excessive amounts of active ingredient, creating risks that are separate from the pharmacologic effects of the peptide itself.

Uncertain long-term safety: For substances with little or no human exposure data, the longer-term safety profile may remain uncertain. The FDA's April 2026 assessment notes limited or insufficient human safety information for several nominated peptides, including BPC-157, AOD-9604, KPV, MOTS-C, and TB-500.

Unverified or gray-market sources: Products obtained through unverified or gray-market sources introduce additional uncertainty about identity, potency, purity, sterility, and storage. A product sold online as a research compound therefore provides no reliable assurance that the substance, concentration, or quality matches what is stated on the label.

How are peptides taken?

Peptide therapies can be administered through different routes depending on the specific product and its formulation. Common routes include injection, oral administration, topical application, and intranasal delivery. For example, semaglutide is available in injectable and oral formulations, while bremelanotide is administered by subcutaneous injection. Some investigational peptides have also been studied through intranasal or topical routes. The route is determined by the product's formulation and intended use.

How to verify a compounding pharmacy

If you are using a compounded peptide, verify the pharmacy or outsourcing facility that actually dispenses or prepares the product. A clinic or telehealth company may arrange the prescription without being the pharmacy itself, so identify the dispensing facility first.

Verify the pharmacy's license. Check the pharmacy's name and location with the relevant state board of pharmacy and confirm that its license is current and that there are no relevant disciplinary actions. The National Association of Boards of Pharmacy (NABP) maintains a directory that can help you locate the appropriate state board.

If the facility claims 503B status, verify the registration. Search the FDA's current list of registered outsourcing facilities and confirm that the facility's name and location appear there.¹⁸ FDA's list also provides information such as the most recent inspection, whether a Form FDA 483 was issued, and whether a recall was conducted.

Review FDA records when relevant. FDA's compounding enforcement database provides access to inspection findings, Form FDA 483s, warning letters, recalls, and other regulatory actions. A Form FDA 483 records investigators' observations during an inspection; it is not, by itself, a final FDA determination of a violation.

Consider accreditation as additional information. Voluntary accreditation can provide information about a pharmacy's quality systems and practices, but it is separate from state licensure, FDA 503B registration, FDA inspection findings, and approval of an individual drug.

What does peptide therapy cost?

There is no single price for peptide therapy because "peptide therapy" can refer to very different treatments. The cost can change with the specific peptide, dose, and formulation, as well as whether the medication is FDA-approved or compounded. Insurance coverage can make a substantial difference for approved medications, while compounded treatment is usually paid out of pocket. The total price may also include the prescribing visit, laboratory testing, pharmacy or dispensing fees, and shipping.

What should you ask your clinician about peptide therapy?

A useful conversation about peptide therapy should go beyond how to take the medication or what results to expect. You should understand exactly what is being proposed, why it is being recommended for you, and how much evidence supports that particular use.

Start by asking your clinician which peptide or drug is being proposed and what it is intended to treat, then clarify its regulatory status. Is it FDA-approved for that indication, being used off-label, compounded, or still investigational? Ask what human evidence supports its use for your specific condition or goal, and what is still uncertain about its safety or effectiveness.

The discussion should also cover how you will be monitored, including any follow-up or laboratory testing that may be appropriate, and what side effects or other risks would warrant contacting your clinician. It is also reasonable to ask whether an FDA-approved or better-established treatment is available for the same purpose.

Finally, if the medication will be compounded, find out which pharmacy will dispense it and how that pharmacy can be verified. Knowing where the medication comes from is part of understanding the treatment itself.

Frequently asked questions

Why are some peptides available from compounding pharmacies if they are not FDA-approved?

Compounding pharmacies can prepare certain medications under specific federal and state requirements when applicable conditions are met. Compounding does not require the resulting drug to have FDA approval, but the substance and the compounding process must still meet the requirements that apply to the pharmacy or outsourcing facility.

What does "research use only" mean when a peptide is sold online?

"Research use only" means the product is represented as being intended for research and not for human use. The label does not establish that the product is FDA-approved or safe for human administration. On March 31, 2026, FDA issued a warning letter to a peptide seller whose products carried research-use-only or similar labels but were marketed to the public in ways that indicated intended human use.¹⁹

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved medication. In July 2026, FDA's Pharmacy Compounding Advisory Committee recommended BPC-157 for possible inclusion on the 503A Bulks List, but that recommendation is advisory only and does not by itself authorize its use in compounding or establish FDA approval.

How do I verify a compounding pharmacy?

Identify the pharmacy that actually dispenses the product (not the clinic that arranged the prescription), verify its state license through the relevant state board of pharmacy, and if it claims 503B status, confirm the registration on FDA's current list of registered outsourcing facilities. FDA's compounding enforcement database also lists inspection findings, Form FDA 483 observations, warning letters, and recalls.

Are compounded peptides safe?

Compounded drugs are not FDA-approved and do not undergo premarket safety review. Their safety depends on the substance, the compounder, and the compounding conditions. FDA has flagged concerns for several nominated peptides including potential immunogenicity from peptide aggregation, API characterization issues, contamination risks, and limited human safety information.

Related reading

Longevity

Longevity medicine: separating science from marketing

What actually extends healthspan on current human evidence — and what's still a well-marketed hypothesis.

GLP-1

GLP-1 medications, explained clearly

Semaglutide, tirzepatide, and the whole class — how they work, who they're for, and what to expect.

Longevity

Does glutathione work? What human research shows

A careful review of the human trials on dose, formulation, and clinical outcomes.

← All articles